Sequential PD-1 and LAG-3 Therapy After CCRT for NSCLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for unresectable, locally advanced non-small cell lung cancer (NSCLC) have suboptimal patient outcomes, with a need for improved therapeutic methods that address the heterogeneity of this disease and provide effective treatment options beyond definitive concurrent chemoradiotherapy.
Innovation Solution
A combination therapy involving programmed death-1 (PD-1) pathway inhibitors and lymphocyte activation gene-3 (LAG-3) antagonists, administered sequentially with a recovery period following chemoradiotherapy, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If definitive concurrent chemoradiotherapy followed by durvalumab maintenance is used, then treatment standard is established, but patient outcomes remain suboptimal with large fraction of patients without appropriate treatment options
Solution Approach 1:
The treatment protocol is segmented into distinct phases: concurrent chemoradiotherapy phase, recovery period, and subsequent combination immunotherapy phase (PD-1 inhibitor plus LAG-3 antagonist). This segmentation allows each phase to be optimized independently while addressing the heterogeneity of disease progression and patient response patterns.
Solution Approach 2:
The treatment approach transitions dynamically from conventional chemoradiotherapy to a combination immunotherapy regimen based on patient response and disease characteristics. The protocol adapts treatment selection and sequencing based on tumor biology, patient tolerance, and response criteria, enabling personalized treatment dynamics.
2Adaptability or versatility
If multi-modality treatment paradigms are applied to unresectable Stage III NSCLC, then treatment coverage is expanded, but disease heterogeneity requires challenging treatment approaches
Solution Approach 1:
The protocol applies local quality by selecting specific treatment modalities based on local disease characteristics and patient-specific factors. Treatment intensity, sequencing, and combination strategies are adjusted according to the specific presentation, stage, and biological features of each patient's tumor, rather than applying a uniform approach.
Solution Approach 2:
The treatment paradigm utilizes parameter changes by modifying treatment timing, duration, and combination based on response criteria and patient status. The protocol adjusts immunotherapy initiation timing based on recovery from chemoradiotherapy, and modifies treatment duration and intensity based on disease response and patient tolerance parameters.
3Reliability
If PD-1 pathway inhibitor and LAG-3 antagonist combination therapy is administered, then immune response is enhanced and treatment outcomes improve, but treatment sequencing and recovery period requirements increase complexity
Solution Approach 1:
The protocol incorporates a recovery period between chemoradiotherapy and the initiation of combination immunotherapy, allowing preliminary tissue healing and immune system stabilization. This preliminary action reduces the risk of overlapping toxicities and optimizes the immune system's ability to respond to subsequent immunotherapy.
Solution Approach 2:
The treatment maintains continuity of useful action by seamlessly transitioning from chemoradiotherapy to combination immunotherapy based on patient response and tolerance. The protocol ensures continuous disease control through coordinated timing of treatment phases, preventing disease progression gaps while managing treatment-related toxicities.
Data Source
AI summary
The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.